Keytruda and Oxygen for Treating Cancers of the Lung, Liver, Colon, and Melanoma

 

                                                             Majid Ali, M.D.

September 10, 2014

Keytruda is claimed to be a brand new, highly effective, and non-toxic cancer drug. It was approved by the FDA in summer of 2014 for treating cancers of lung, liver, colon, melanoma and some other cancers. This would be great news if doctors without financial ties with the drug maker can validate the initial claims of drug efficacy. It seems safe to predict that this will happen only if the oxygen systems of the body can be preserved. It would be a serious mistake to think that Keytruda can eradicate cancer long-term if the health-preserving oxygen systems of the body are weakened.

Oxygen Protocol for Cancer Control

I tell my patients receiving chemotherapy for cancer to be very diligent to keep their oxygen systems working well because the long-term results in most cases depend more on oxygen than on chemotherapy. For preserving oxygen systems, my priorities are: (1) spiritual healing; (2) gentle daily bowel-blood-liver detox; (3) gentle limbic exercise; (4) spices; (5) herbs; (6) castor and other oils; and (7) nutrient supplementation.

Oxygen, the Motivator; Oxygen, the Disciplinarian

Oxygen is the organizing principal of human biology and governs the aging process. In the evolutionary “oxygen kaleidoscope of life,” one would expect oxygen to be both a great motivator and a strict disciplinarian for all cells in the body, promoting cellular perfection of means and damming down cellular confusion of goals when that develops—old Albert had it right. Oxygen has its own order of gas pedals and brake pedals.

The oxygen kaleidoscope of life has many molecular checkpoint pathways to prevent mutated and malignant (cancer by another name) cells from multiplying rapidly, forming tumor masses, and then striking out with distant metastasis. Some of these pathways negatively regulate cellular defense functions—functioning as “cellular brakes” so to speak—of T and B lymphocytes. Under oxygen-deprived conditions, malignant cells survive by activating these cellular brakes and disabling cellular defenses. Notable among such cellular self-braking pathways are BRAF, CTLA-4, and PD-1 systems.

Keytruda, the First PD-1 De-Braking Cancer Drug

Keytruda is the first member of a novel class of drugs that facilitates death of cancer cells by inhibiting the action of one PD-1 de-braking system. This is the basis of the claim that Keytruda can destroy many aggressive cancers without using cytotoxic chemotherapy. Of course, similar claims were made about many other cancer drugs that proved false. Notably among them is the case of Avastin, an angiogenessis-inhibiting drug, which earned billions for its makers before the FDA revoked the drug approval.

Like other new cancer drugs, Keytruda (generic name, pembrolizumab) is very expensive. Merck, the maker of the drug, revealed that it will cost about $12,500 a month (about $150,000 a year).

Oxygen Protocol for Cancer Control

I offer details of my Oxygen Protocol for Cancer Control in my two-volume book entitled “The Crab, Oxygen and Cancer. Volume I: The Dysox Model of Cancer.” (2007). Available at www.aliacademy.org.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s